Your choices regarding cookies on this site

Webinar|November 15, 2023
This webinar was featured live November 15, 2023. Please register to view the recording.
RegisterThe FDA approved 37 new drugs last year, including novel treatments for cancer and a blockbuster drug for type 2 diabetes. If you’re a life or health underwriter, you need to know what these breakthrough drugs imply for risk assessment. In addition, several familiar drugs were approved for use in new settings, so their appearance on a profile might now signal significantly different levels of risk.
In this one-hour webinar, we’ll survey some of the most interesting and relevant new therapeutics and show you how the Irix® Suite of risk assessment tools, drawing on both Prescription Data and Medical Data, can instantly deliver an up-to-date, empirical picture of almost any applicant’s health. Join us, then underwrite with confidence when you see these novel drugs, or drugs with supplemental indications, on a profile.
Medical directors, underwriters, and other clinical professionals working in the insurance industry will benefit from a review of significant new drug therapies—and a refresher on insurtech tools we constantly update with the latest clinical and data science.
Matt Glasow, PharmD, MBA
Clinical Conslutant
Milliman and our third-party website analytics and performance partners use cookies on our website that may collect and use personal information in order to constantly improve website performance and reliability and to provide accurate and relevant information. By clicking “Accept,” you consent to the placement and use of cookies by Milliman and our third-party partners for these purposes. You can learn more about how this site uses cookies and related technologies by reading our privacy policy